OncoMatch/Clinical Trials/NCT06371157
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
Is NCT06371157 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including AK104 and Lenvatinib for hepatocellular carcinoma.
Treatment: AK104 · Lenvatinib — A study to evaluate cadonilimab (AK104) + lenvatinib in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic hepatocellular carcinoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Hepatocellular Carcinoma
Disease stage
Excluded: Stage IV
No evidence of metastasis; Not amenable to curative surgery or transplantation or curative ablation but amenable to TACE
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Liver function
child pugh score class a
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06371157 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages